Top

Published in:

Open Access 01-12-2008 | Original investigation

Metabolic syndrome is not associated with reduction in aortic distensibility in subjects with type 2 diabetes mellitus

Authors: Nicholas Tentolouris, Athanasia Papazafiropoulou, Ioannis Moyssakis, Stavros Liatis, Despoina Perrea, Maria Kostakis, Nicholas Katsilambros

Published in: Cardiovascular Diabetology | Issue 1/2008

Abstract

Background

Aortic distensibility (AD) is a marker of the elastic properties of the aorta. Reduction of AD occurs early in subjects with type 2 diabetes mellitus (T2DM) and it is associated with subclinical generalized atherosclerosis. Metabolic syndrome (MetS) is common in subjects with T2DM and predicts cardiovascular morbidity and mortality. This study examined the potential relationship between MetS and AD in a cohort of subjects with T2DM.

Methods and results

A total of 210 subjects with T2DM were studied. MetS was diagnosed using the NCEP/ATP-III criteria. AD was assessed non-invasively by ultrasonography. The prevalence of MetS was 64.8%. AD was not significantly different between subjects with and without MetS (1.80 ± 0.54 vs. 1.84 ± 0.53 10^-6 dyn^-1 cm², p = 0.55). Univariate linear regression analysis showed that AD was associated positively with male sex (p = 0.02) as well as glomerular filtration rate (p < 0.001), and negatively with age (p = 0.04), history of hypertension (p = 0.001), as well as duration of diabetes (p < 0.001). After multivariate adjustment, AD was associated independently and significantly only with age (p = 0.02), duration of diabetes p < 0.001), and history of hypertension (p = 0.004); no significant relationship was found with MetS status, the sum of the components of the MetS or the individual components-besides hypertension-of the MetS.

Conclusion

In subjects with T2DM, MetS status per se is not associated with reduction of AD. In addition, it was shown that besides ageing, duration of glycemia was a strong predictor of AD. From the components of the MetS only hypertension was associated with reduction of the elastic properties of the aorta.

Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993, 16: 434-444. 10.2337/diacare.16.2.434.CrossRefPubMed

Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB: Mortality among diabetics in a national sample. Am J Epidemiol. 1988, 128: 389-401.PubMed

Tentolouris N, Liatis S, Moyssakis I, Tsapogas P, Psallas M, Diakoumopoulou E, Voteas V, Katsilambros N: Aortic distensibility is reduced in subjects with type 2 diabetes and cardiac autonomic neuropathy. Eur J Clin Invest. 2003, 33: 1075-1083. 10.1111/j.1365-2362.2003.01279.x.CrossRefPubMed

Stefanadis C, Stratos C, Boudoulas H, Kourouklis C, Toutouzas P: Distensibility of the ascending aorta: comparison of invasive and non-invasive techniques in healthy men and in men with arterial disease. Eur Heart J. 1990, 11: 990-996.PubMed

Hopkins KD, Lehmann ED, Gosling RG: Aortic compliance measurements: a non-invasive indicator of atherosclerosis?. Lancet. 1994, 343: 1447-10.1016/S0140-6736(94)92577-1.CrossRefPubMed

Reaven GM: Banting lecture 1988: Role of insulin resistance in human disease. Diabetes. 1988, 37: 1595-1607. 10.2337/diabetes.37.12.1595.CrossRefPubMed

Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001, 24: 683-689. 10.2337/diacare.24.4.683.CrossRefPubMed

Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM, San Antonio Heart Study: The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care. 2003, 26: 3153-3159. 10.2337/diacare.26.11.3153.CrossRefPubMed

McNeill AM, Rosamond WD, Girman CJ, Heiss G, Golden SH, Duncan BB, East HE, Ballantyne C: Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol. 2004, 94: 1249-1254. 10.1016/j.amjcard.2004.07.107.CrossRefPubMed

10.

Czernichow S, Bertrais S, Blacher J, Oppert JM, Galan P, Ducimetière P, Hercberg S, Safar M, Zureik M, SU.VI.MAX. Vascular Study: Metabolic syndrome in relation to structure and function of large arteries: a predominant effect of blood pressure. A report from the SU.VI.MAX. Vascular Study. Am J Hypertens. 2005, 18: 1154-1160. 10.1016/j.amjhyper.2005.04.006.CrossRefPubMed

11.

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997, 20: 1183-1197.

12.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003, 42: 1206-1252. 10.1161/01.HYP.0000107251.49515.c2.CrossRefPubMed

13.

Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preperative ultracentrifuge. Clin Chem. 1972, 18: 499-502.PubMed

14.

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999, 130: 461-470.CrossRefPubMed

15.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28: 412-419. 10.1007/BF00280883.CrossRefPubMed

16.

Boudoulas H, Wooley CF: Aortic Function. Functional abnormalities of the aorta. Edited by: Toutouzas PK, Wooley CF. 1996, Armonk, New York: Futura publishing Co, 3-36.

17.

Relimpio F, Martinez-Brocca MA, Leal-Cerro A, Losada F, Mangas MA, Pumar A, Astorga R: Variability in the presence of the metabolic syndrome in Type 2 diabetic patients attending a diabetes clinic. Influences of age and gender. Diabetes Res Clin Pract. 2004, 65: 135-142. 10.1016/j.diabres.2003.12.003.CrossRefPubMed

18.

Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, Prina Cerai S, Pagano G, Cavallo-Perin P, Casale Monferrato Study: Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care. 2004, 27: 2689-2694. 10.2337/diacare.27.11.2689.CrossRefPubMed

19.

Marchesini G, Forlani G, Cerrelli F, Manini R, Natale S, Baraldi L, Ermini G, Savorani G, Zocchi D, Melchionda N: WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabet Med. 2004, 21: 383-387. 10.1111/j.1464-5491.2004.01115.x.CrossRefPubMed

20.

Kompoti M, Mariolis A, Alevizos A, Kyrazis I, Protopsaltis I, Dimou E, Lentzas I, Levisianou D, Gova A, Melidonis A: Elevated serum triglycerides is the strongest single indicator for the presence of metabolic syndrome in patients with type 2 diabetes. Cardiovasc Diabetol. 2006, 5: 21-10.1186/1475-2840-5-21.PubMedCentralCrossRefPubMed

21.

Martens FM, van der Graaf Y, Dijk JM, Olijhoek JK, Visseren FL: Carotid arterial stiffness is marginally higher in the metabolic syndrome and markedly higher in type 2 diabetes mellitus in patients with manifestations of arterial disease. Atherosclerosis.

22.

Maple-Brown L, Cunningham J, Celermajer DS, O'Dea K: Increased carotid intima-media thickness in remote and urban Indigenous Australians: impact of diabetes and components of the metabolic syndrome. Clin Endocrinol (Oxf). 2007, 66: 419-425. 10.1111/j.1365-2265.2007.02749.x.CrossRef

23.

Kilpatrick ES, Rigby AS, Atkin SL: Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care. 2007, 30: 702-712.

24.

Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and the prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes Care. 2003, 52: 1210-1214.CrossRef

25.

Hopkins KD, Lehmann ED, Jones RL, Turay RC, Gosling RG: A family history of NIDDM is associated with decreased aortic distensibility in normal healthy young adult subjects. Diabetes Care. 1996, 19: 501-503. 10.2337/diacare.19.5.501.CrossRefPubMed

26.

Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ: The role of glycation cross-links in diabetic vascular stiffening. Diabetologia. 1996, 39: 946-951. 10.1007/BF00403914.CrossRefPubMed

27.

Chappey O, Dosquet C, Wautier MP, Wautier JL: Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest. 1997, 27: 97-108. 10.1046/j.1365-2362.1997.710624.x.CrossRefPubMed

28.

Ahlgren AR, Sundkvist G, Wollmer P, Sonesson B, Lanne T: Increased aortic stiffness in women with type 1 diabetes mellitus is associated with diabetes duration and autonomic nerve function. Diabet Med. 1999, 16: 291-297. 10.1046/j.1464-5491.1999.00079.x.CrossRefPubMed

29.

De Angelis L, Millasseau SC, Smith A, Viberti G, Jones RH, Ritter JM, Chowienczyk PJ: Sex differences in age-related stiffening of the aorta in subjects with type 2 diabetes. Hypertension. 2004, 44: 67-71. 10.1161/01.HYP.0000130482.81883.fd.CrossRefPubMed

30.

Lehmann ED, Hopkins KD, Gosling RG: Increased aortic stiffness in women with NIDDM. Diabetologia. 1996, 39: 870-871. 10.1007/s001250050526.CrossRefPubMed

31.

UKPDS 38: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998, 317: 703-713.CrossRef

32.

Tentolouris N, Papazafiropoulou A, Liatis S, Moyssakis I, Perrea D, Soldatos RP, Katsilambros N: Components of the metabolic syndrome, but not the metabolic syndrome per se, are associated with aortic distensibility. Nutr Metab Cardiovasc Dis.

33.

Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A: Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001, 37: 1236-1241.CrossRefPubMed

34.

De Angelis L, Millasseau SC, Smith A, Viberti G, Jones RH, Ritter JM, Chowienczyk PJ: Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004, 43: 1239-1245. 10.1161/01.HYP.0000128420.01881.aa.CrossRef

35.

Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998, 15: 539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.CrossRefPubMed

Title: Metabolic syndrome is not associated with reduction in aortic distensibility in subjects with type 2 diabetes mellitus
Authors: Nicholas Tentolouris
Athanasia Papazafiropoulou
Ioannis Moyssakis
Stavros Liatis
Despoina Perrea
Maria Kostakis
Nicholas Katsilambros
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2008
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/1475-2840-7-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Metabolic syndrome is not associated with reduction in aortic distensibility in subjects with type 2 diabetes mellitus

Abstract

Background

Methods and results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods and results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

Eptifibatide and abciximab inhibit insulin-induced focal adhesion formation and proliferative responses in human aortic smooth muscle cells

In vivo endothelial gene regulation in diabetes

Development and validation of a risk score for hospitalization for heart failure in patients with Type 2 Diabetes Mellitus

Are the adverse effects of glitazones linked to induced testosterone deficiency?

Prevalence of abnormal glucose metabolism in atrial fibrillation: A case control study in 75-year old subjects

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page